Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy
Abstract Background Severe ventricular rhythm disturbances are the hallmark of arrhythmogenic cardiomyopathy (ACM), and are often explained by structural conduction abnormalities. However, comprehensive investigations of ACM cell electrical instability are lacking. This study aimed to elucidate earl...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Clinical and Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/ctm2.319 |
id |
doaj-c9664adcb3fe4088aa3cbb1ca8360b5b |
---|---|
record_format |
Article |
spelling |
doaj-c9664adcb3fe4088aa3cbb1ca8360b5b2021-03-30T14:25:35ZengWileyClinical and Translational Medicine2001-13262021-03-01113n/an/a10.1002/ctm2.319Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapyAdrien Moreau0Jean‐Baptiste Reisqs1Helene Delanoe‐Ayari2Marion Pierre3Alexandre Janin4Antoine Deliniere5Francis Bessière6Albano C. Meli7Azzouz Charrabi8Estele Lafont9Camille Valla10Delphine Bauer11Elodie Morel12Vincent Gache13Gilles Millat14Xavier Nissan15Adele Faucherre16Chris Jopling17Sylvain Richard18Alexandre Mejat19Philippe Chevalier20PhyMedExp INSERM U1046 CNRS UMR9214 Université de Montpellier Montpellier FrancePhyMedExp INSERM U1046 CNRS UMR9214 Université de Montpellier Montpellier FranceInstitut lumière matière Claude Bernard University, Lyon 1 Villeurbanne FrancePhyMedExp INSERM U1046 CNRS UMR9214 Université de Montpellier Montpellier FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceService de Rythmologie Hospices Civils de Lyon Lyon FranceService de Rythmologie Hospices Civils de Lyon Lyon FrancePhyMedExp INSERM U1046 CNRS UMR9214 Université de Montpellier Montpellier FrancePhyMedExp INSERM U1046 CNRS UMR9214 Université de Montpellier Montpellier FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceCECS I‐Stem Corbeil‐Essonnes FranceIGF, CNRS, INSERM Université de Montpellier Montpellier FranceIGF, CNRS, INSERM Université de Montpellier Montpellier FrancePhyMedExp INSERM U1046 CNRS UMR9214 Université de Montpellier Montpellier FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceAbstract Background Severe ventricular rhythm disturbances are the hallmark of arrhythmogenic cardiomyopathy (ACM), and are often explained by structural conduction abnormalities. However, comprehensive investigations of ACM cell electrical instability are lacking. This study aimed to elucidate early electrical myogenic signature of ACM. Methods We investigated a 41‐year‐old ACM patient with a missense mutation (c.394C>T) in the DSC2 gene, which encodes desmocollin 2. Pathogenicity of this variant was confirmed using a zebrafish DSC2 model system. Control and DSC2 patient‐derived pluripotent stem cells were reprogrammed and differentiated into cardiomyocytes (hiPSC‐CM) to examine the specific electromechanical phenotype and its modulation by antiarrhythmic drugs (AADs). Samples of the patient's heart and hiPSC‐CM were examined to identify molecular and cellular alterations. Results A shortened action potential duration was associated with reduced Ca2+ current density and increased K+ current density. This finding led to the elucidation of previously unknown abnormal repolarization dynamics in ACM patients. Moreover, the Ca2+ mobilised during transients was decreased, and the Ca2+ sparks frequency was increased. AAD testing revealed the following: (1) flecainide normalised Ca2+ transients and significantly decreased Ca2+ spark occurrence and (2) sotalol significantly lengthened the action potential and normalised the cells’ contractile properties. Conclusions Thorough analysis of hiPSC‐CM derived from the DSC2 patient revealed abnormal repolarization dynamics, prompting the discovery of a short QT interval in some ACM patients. Overall, these results confirm a myogenic origin of ACM electrical instability and provide a rationale for prescribing class 1 and 3 AADs in ACM patients with increased ventricular repolarization reserve.https://doi.org/10.1002/ctm2.319action potential durationarrhythmogenic cardiomyopathydesmocollinhiPSC‐CMQT duration |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Adrien Moreau Jean‐Baptiste Reisqs Helene Delanoe‐Ayari Marion Pierre Alexandre Janin Antoine Deliniere Francis Bessière Albano C. Meli Azzouz Charrabi Estele Lafont Camille Valla Delphine Bauer Elodie Morel Vincent Gache Gilles Millat Xavier Nissan Adele Faucherre Chris Jopling Sylvain Richard Alexandre Mejat Philippe Chevalier |
spellingShingle |
Adrien Moreau Jean‐Baptiste Reisqs Helene Delanoe‐Ayari Marion Pierre Alexandre Janin Antoine Deliniere Francis Bessière Albano C. Meli Azzouz Charrabi Estele Lafont Camille Valla Delphine Bauer Elodie Morel Vincent Gache Gilles Millat Xavier Nissan Adele Faucherre Chris Jopling Sylvain Richard Alexandre Mejat Philippe Chevalier Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy Clinical and Translational Medicine action potential duration arrhythmogenic cardiomyopathy desmocollin hiPSC‐CM QT duration |
author_facet |
Adrien Moreau Jean‐Baptiste Reisqs Helene Delanoe‐Ayari Marion Pierre Alexandre Janin Antoine Deliniere Francis Bessière Albano C. Meli Azzouz Charrabi Estele Lafont Camille Valla Delphine Bauer Elodie Morel Vincent Gache Gilles Millat Xavier Nissan Adele Faucherre Chris Jopling Sylvain Richard Alexandre Mejat Philippe Chevalier |
author_sort |
Adrien Moreau |
title |
Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy |
title_short |
Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy |
title_full |
Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy |
title_fullStr |
Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy |
title_full_unstemmed |
Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy |
title_sort |
deciphering dsc2 arrhythmogenic cardiomyopathy electrical instability: from ion channels to ecg and tailored drug therapy |
publisher |
Wiley |
series |
Clinical and Translational Medicine |
issn |
2001-1326 |
publishDate |
2021-03-01 |
description |
Abstract Background Severe ventricular rhythm disturbances are the hallmark of arrhythmogenic cardiomyopathy (ACM), and are often explained by structural conduction abnormalities. However, comprehensive investigations of ACM cell electrical instability are lacking. This study aimed to elucidate early electrical myogenic signature of ACM. Methods We investigated a 41‐year‐old ACM patient with a missense mutation (c.394C>T) in the DSC2 gene, which encodes desmocollin 2. Pathogenicity of this variant was confirmed using a zebrafish DSC2 model system. Control and DSC2 patient‐derived pluripotent stem cells were reprogrammed and differentiated into cardiomyocytes (hiPSC‐CM) to examine the specific electromechanical phenotype and its modulation by antiarrhythmic drugs (AADs). Samples of the patient's heart and hiPSC‐CM were examined to identify molecular and cellular alterations. Results A shortened action potential duration was associated with reduced Ca2+ current density and increased K+ current density. This finding led to the elucidation of previously unknown abnormal repolarization dynamics in ACM patients. Moreover, the Ca2+ mobilised during transients was decreased, and the Ca2+ sparks frequency was increased. AAD testing revealed the following: (1) flecainide normalised Ca2+ transients and significantly decreased Ca2+ spark occurrence and (2) sotalol significantly lengthened the action potential and normalised the cells’ contractile properties. Conclusions Thorough analysis of hiPSC‐CM derived from the DSC2 patient revealed abnormal repolarization dynamics, prompting the discovery of a short QT interval in some ACM patients. Overall, these results confirm a myogenic origin of ACM electrical instability and provide a rationale for prescribing class 1 and 3 AADs in ACM patients with increased ventricular repolarization reserve. |
topic |
action potential duration arrhythmogenic cardiomyopathy desmocollin hiPSC‐CM QT duration |
url |
https://doi.org/10.1002/ctm2.319 |
work_keys_str_mv |
AT adrienmoreau decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT jeanbaptistereisqs decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT helenedelanoeayari decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT marionpierre decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT alexandrejanin decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT antoinedeliniere decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT francisbessiere decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT albanocmeli decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT azzouzcharrabi decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT estelelafont decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT camillevalla decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT delphinebauer decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT elodiemorel decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT vincentgache decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT gillesmillat decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT xaviernissan decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT adelefaucherre decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT chrisjopling decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT sylvainrichard decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT alexandremejat decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy AT philippechevalier decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy |
_version_ |
1724180596338458624 |